TLDR Tesla reports Q3 2025 earnings today after market close with Wall Street expecting EPS of $0.56 on revenue of $27.3 billion The company delivered 497,099 vehicles in Q3, beating analyst estimates of 443,079 and showing strong performance despite market challenges Cantor Fitzgerald analyst Andres Sheppard maintains Buy rating with $355 price target, urging focus [...] The post Tesla (TSLA) Stock: Earnings Day Arrives With Eyes on Robotaxi and Self-Driving Future appeared first on Blockonomi.TLDR Tesla reports Q3 2025 earnings today after market close with Wall Street expecting EPS of $0.56 on revenue of $27.3 billion The company delivered 497,099 vehicles in Q3, beating analyst estimates of 443,079 and showing strong performance despite market challenges Cantor Fitzgerald analyst Andres Sheppard maintains Buy rating with $355 price target, urging focus [...] The post Tesla (TSLA) Stock: Earnings Day Arrives With Eyes on Robotaxi and Self-Driving Future appeared first on Blockonomi.

Tesla (TSLA) Stock: Earnings Day Arrives With Eyes on Robotaxi and Self-Driving Future

TLDR

  • Tesla reports Q3 2025 earnings today after market close with Wall Street expecting EPS of $0.56 on revenue of $27.3 billion
  • The company delivered 497,099 vehicles in Q3, beating analyst estimates of 443,079 and showing strong performance despite market challenges
  • Cantor Fitzgerald analyst Andres Sheppard maintains Buy rating with $355 price target, urging focus on robotaxi rollout, FSD adoption, and Optimus robot development
  • Tesla faces headwinds from eliminated $7,500 EV tax credit, U.S. tariffs, and increased competition from Chinese automakers
  • Key catalysts ahead include robotaxi expansion beyond Austin, Cybercab launch next year, FSD rollout in China and Europe, and November 6 shareholder vote on Musk’s compensation package

Tesla reports its third-quarter fiscal 2025 earnings after today’s market close. Investors are watching closely.

Wall Street expects earnings per share of 56 cents on revenue of $27.3 billion. The company needs to beat both numbers to satisfy the market.


TSLA Stock Card
Tesla, Inc., TSLA

The earnings come after Tesla delivered 497,099 vehicles in Q3. That beat analyst expectations of 443,079 units by a healthy margin.

Cantor Fitzgerald analyst Andres Sheppard rates Tesla as a Buy with a $355 price target. He says investors should focus less on traditional metrics and more on the company’s robotaxi and autonomy businesses.

Since the Q2 report on July 23, Tesla stock has jumped over 44%. The company launched Full Self-Driving version 14 and made progress on its Optimus robot and Cybercab projects.

Sheppard points out that U.S. tariffs are creating problems. The elimination of the $7,500 EV tax credit also hurts demand.

Chinese automakers are bringing more competition to the market. These factors have pressured the EV industry as a whole.

Investors want to hear CEO Elon Musk discuss timing for several key developments. The robotaxi rollout tops that list.

Robotaxi Expansion and Product Pipeline

Tesla launched its self-driving taxi service in Austin, Texas, in July. The company has expanded coverage within Austin but hasn’t added new cities yet.

The Cybercab launch is scheduled for next year. Investors want concrete dates and production plans.

FSD adoption in China and Europe represents a major growth opportunity. Regulatory approval timelines remain unclear.

Tesla recently introduced lower-priced Standard trims of the Model Y and Model 3. The move aims to offset the loss of the federal tax credit.

Orders for these more affordable versions will be a key topic on the earnings call. Pricing strategy matters more now without government incentives.

Production Targets and Profit Margins

Tesla has produced and delivered about 1.2 million vehicles globally this year. Sheppard expects a weaker fourth quarter.

He lowered delivery estimates to around 1.61 million for 2025. For 2026, he projects 1.86 million vehicles.

Revenue forecasts dropped to $94.4 billion for 2025 and $107.8 billion for 2026. These cuts reflect the challenging environment.

Automotive gross profit margins excluding regulatory credits are projected at 15.5% for Q3. That compares to 15% in Q2.

Peak margins hit 30% in the first quarter of 2022. Getting back to those levels looks difficult in the current market.

The delivery beat should translate to roughly $2.4 billion in additional sales. Wall Street estimates for automotive sales sit at $20.6 billion.

Analysts haven’t fully adjusted their models for the better delivery numbers. This could set up an earnings beat.

CEO Commitment and Shareholder Vote

Musk recently purchased roughly 2.5 million Tesla shares. The move signals his long-term commitment to the company.

Shareholders will vote on his trillion-dollar pay package at the November 6 Annual Shareholder Meeting. The vote comes after a Delaware court voided his previous compensation plan.

Analysts give Tesla a Hold consensus rating with 16 Buy, 13 Hold, and 10 Sell ratings. The average price target of $369.80 implies downside from current levels.

Tesla stock has gained 9.6% year-to-date. Over the past six months, shares have surged 95%.

Earnings estimates for 2026 have fallen roughly 33% during that same six-month period. The disconnect between stock performance and earnings revisions is stark.

Management commentary on the Optimus humanoid robot will also draw attention. Sales are expected to begin in 2026.

The post Tesla (TSLA) Stock: Earnings Day Arrives With Eyes on Robotaxi and Self-Driving Future appeared first on Blockonomi.

Market Opportunity
FUTURECOIN Logo
FUTURECOIN Price(FUTURE)
$0.12448
$0.12448$0.12448
+0.02%
USD
FUTURECOIN (FUTURE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23